Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update
PR Newswire•26/10/2026•08:01 ET
0
Key Highlights
- ➤Acurx will report third-quarter 2026 financial results November 12 before U.S. markets open
- ➤First multiply-recurrent CDI trial patient enrolled in September 2026
- ➤Pilot trial will enroll 20 patients with at least three prior CDI episodes
- ➤FDA agreed on pivotal Phase 3 acute CDI trial design and registration safety database
- ➤Acurx plans international Phase 3 acute CDI trials subject to funding
Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update PR Newswire
STATEN ISLAND, N.Y., Oct. 26, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for serious and life threatening bacterial infections, announced today that the Company will discuss its third quarter 2026 financial results on Thursday, November 12, 2026 at 8:00 am ET before the U.S. financial markets open.
Get started
Create a free account to read the full story.